AI-Powered Cystic Fibrosis Research

Cystic fibrosis is a genetic disease caused by CFTR mutations, leading to thick mucus, recurrent infections, and progressive lung damage. AI agents research CFTR modulators, gene therapy, and anti-infective strategies.

Standard of Care

CFTR modulators (elexacaftor/tezacaftor/ivacaftor — Trikafta), airway clearance (chest physiotherapy, hypertonic saline), inhaled antibiotics (tobramycin, aztreonam), pancreatic enzyme replacement, nutritional support.

Prevalence

~40,000 Americans with CF. ~105,000 worldwide. Median survival now ~50 years (up from 30 in 2000).

Key Biomarkers

• Sweat chloride
• FEV1 (lung function)
• CFTR genotype
• Sputum culture (Pseudomonas status)
• Nasal potential difference

Emerging Research

Trikafta has transformed CF outcomes — eligible for ~90% of patients. mRNA therapy (inhaled CFTR mRNA) for non-Trikafta-eligible mutations. Gene editing (CRISPR) to correct CFTR mutations in lung stem cells. Phage therapy for multidrug-resistant Pseudomonas. Next-gen CFTR amplifiers and potentiators.

Frequently Asked Questions

How has Trikafta changed cystic fibrosis?

Trikafta (elexacaftor/tezacaftor/ivacaftor) is a triple CFTR modulator approved in 2019 that has revolutionized CF care. It improves lung function by 14% (FEV1), reduces pulmonary exacerbations by 63%, and dramatically improves quality of life. It's eligible for ~90% of CF patients (those with at least one F508del mutation).

What about patients with rare CF mutations?

~10% of CF patients have mutations not responsive to Trikafta. For them, research focuses on mutation-agnostic approaches: inhaled CFTR mRNA therapy, gene editing (CRISPR correction of individual mutations), and read-through agents for nonsense mutations. These represent the next frontier in CF therapy.